Clinical trials: Organising Pneumonia
Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans)
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
This is a mutli-center open-label study to provide continued supply of itacitinib to participants from the following Incyte-sponsored studies of itacitinib: INCB39110-209, INCB39110-213, INCB39110-214, INCB39110-230, and…
- Conditions
- Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease
- Trial name
- NCT04640025
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 7 more
- Volunteers
- 18 people
- Sponsor
- Incyte Corporation
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.
- Trial name
- NCT01380535
- Testing
- ECP Methoxsalen, Standard of Care
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Kidney Diseases, Chronic Renal Insufficiency
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
Approximately 207 patients with chronic kidney disease (CKD) on hemodialysis will be entered into this study at approximately 26 centers in the United States.
- Conditions
- Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
- Trial name
- NCT00268957
- Testing
- Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
- Where
- 29 sites in United States
- Volunteers
- 217 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Graft Versus Host Disease
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease
- Trial name
- NCT06300320
- Testing
- TQ05105 tablets
- Where
- 12 sites in China
- Volunteers
- 65 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Migraine
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
- Trial name
- NCT00210873
- Testing
- topiramate
- Volunteers
- 200 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Nausea, Vomiting
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have…
- Trial name
- NAVIGATE (NCT06464926)
- Testing
- Enterra Therapy System
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 148 people
- Sponsor
- Enterra Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901302
- Testing
- CB-5945
- Volunteers
- 61 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Graft Versus Host Disease
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
- Trial name
- NCT03790332
- Testing
- Ibrutinib
- Where
- 48 sites in United States, Australia and 11 more
- Volunteers
- 59 people
- Sponsor
- Pharmacyclics LLC.
Bronchiolitis Obliterans, Obliterative Bronchiolitis
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
- Conditions
- Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome
- Trial name
- BOSTON-3 (NCT04039347)
- Testing
- Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg
- Where
- 37 sites in United States, Austria and 7 more
- Volunteers
- 164 people
- Sponsor
- Zambon SpA
SARS-CoV-2 Infection
EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)
Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2 infection based on a qualitative approach.
- Trial name
- WHO (NCT05618561)
- Testing
- EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
- Where
- 5 sites in Croatia, Greece and 1 more
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- AnteoTech Ltd
Wound
Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border
The clinical study will evaluate the safety and effectiveness of the ALLEVYN Gentle Border. The study is a post-market clinical follow-up to assess clinical performance and safety of ALLEVYN Gentle Border with new wound contact…
- Trial name
- NCT03877484
- Testing
- ALLEVYN Gentle border
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Smith & Nephew Orthopaedics AG
Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
This open-label, extension study is designed to provide continuing treatment with RO5045337 to participants who have completed parent studies NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021…
- Trial name
- NCT01677780
- Testing
- RO5045337
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
- Trial name
- NCT01023516
- Testing
- AZD9668
- Where
- 66 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin's Lymphoma
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT01149668
- Testing
- PCI-24781
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pharmacyclics LLC.
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences